Human Fragile Histidine Triad (Recombinant)

Recombinant Human Fragile Histidine Triad (FHIT)

Source: E.Coli

Background: Cleaves A-5\\\'-PPP-5\\\'A to yield AMP and ADP. Possible tumor suppressor for specific tissues Alterations and deletions of the FHIT (Fragile Histidine Triad) gene are strongly linked to the genesis and establishment of human tumors of the lung, cervix, breast, colon, stomach, and pancreas. In normal cells, FHIT may act as a tumor suppressor

Description: Recombinant FHIT shows a band at 43kDa on SDS-PAGE commassie blue stained gel. Recombinant FHIT is purified by proprietary chromatographic techniques.

Physical Appearance: Sterile filtered liquid.

Formulation: 100 g/ml in 50mM Tris-Acetate, pH7.5, 1mM EDTA, 20% Glycerol without BSA and Sodium Azide.

Stability: Store vial at -20Co to -80Co. When stored at the recommended temperature, FHIT is stable for 12 months. Please avoid freeze-thaw cycles.

Purity: Greater than 90.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by reducing and non-reducing SDS-PAGE coomassie blue gel.

Dimers and aggregates: Less than 1% as determined by coomassie blue SDS-PAGE gel analysis.

Endotoxin: Less than 0.1 ng/ g (IEU/ g) of Human FHIT.

Usage: BioWORLD\\\'s products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.